Hematologic complications in patients exposed to PARP inhibitors

Abstract excerpt

<h4>ABSTRACT</h4> Patients with BRCA1/2- mutated ovarian, breast, prostate, or pancreatic tumors can be treated with poly ADP-ribose polymerase (PARP) inhibitors. PARP inhibitors, however, are known to cause therapy-related myeloid neoplasms (t-MN) in a subset of patients. Predisposing factors to t-MN development in the context of PARP inhibitor exposure are not well described. To determine the frequency of t-MN...

Topics

Open a Topic to create a Post that cites this publication.

• Acute Myeloid Leukemia Research
• Carcinoma, Ovarian Epithelial
• Germ-Line Mutation
• Mutation
• Neoplasms, Second Primary
• Ovarian Neoplasms
• PARP inhibition in cancer therapy
• Poly(ADP-ribose) Polymerase Inhibitors

Identifiers and source

Literature Corpus work

56e600fa-7712-50b3-8364-170cc50e271e

DOI

10.1101/2025.07.01.25329998